{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:58:00Z","timestamp":1775152680045,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.jcv.2009.05.029","type":"journal-article","created":{"date-parts":[[2009,6,18]],"date-time":"2009-06-18T08:06:44Z","timestamp":1245312404000},"page":"362-366","source":"Crossref","is-referenced-by-count":1,"title":["Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption"],"prefix":"10.1016","volume":"45","author":[{"given":"Rosario C.","family":"Mata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Flor-Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"P\u00e9rez-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2009.05.029_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(04)16589-6","article-title":"Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes","volume":"364","author":"Ledergerber","year":"2004","journal-title":"Lancet"},{"issue":"9400","key":"10.1016\/j.jcv.2009.05.029_bib3","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","article-title":"University of California SF, San Francisco General Hospital SFCUSAspue. Treatment of antiretroviral-drug-resistant HIV-1 infection","volume":"362","author":"Deeks","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2009.05.029_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001432-200102000-00005","article-title":"Implications of antiretroviral resistance on viral fitness","volume":"14","author":"Nijhuis","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/QAI.0b013e318074f008","article-title":"Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure","volume":"45","author":"De Luca","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2009.05.029_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.aids.0000171400.15619.e1","article-title":"HIV-1 pol replication capacity predicts disease progression","volume":"19","author":"Daar","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2009.05.029_bib7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","article-title":"CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial","volume":"367","author":"Danel","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2009.05.029_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJM200102153440702","article-title":"Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia","volume":"344","author":"Deeks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2009.05.029_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa035103","article-title":"Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus","volume":"349","author":"Lawrence","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2009.05.029_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.qai.0000197078.41150.0d","article-title":"Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children","volume":"41","author":"Abadi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2009.05.029_bib11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/496892","article-title":"Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection","volume":"192","author":"Deeks","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1468-1293.2007.00540.x","article-title":"A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1","volume":"9","author":"Garcia-Perez","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.jcv.2009.05.029_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2009.05.029_bib14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/01.aids.0000186816.99993.8e","article-title":"Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients","volume":"19","author":"Legrand","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2009.05.029_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1086\/510533","article-title":"Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation","volume":"195","author":"van Maarseveen","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib16","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2009.05.029_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2009.05.029_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2009.05.029_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2009.05.029_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/515282","article-title":"Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance","volume":"177","author":"Maeda","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib21","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1128\/JVI.73.5.3744-3752.1999","article-title":"Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1","volume":"73","author":"Martinez-Picado","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2009.05.029_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1086\/323604","article-title":"Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy","volume":"184","author":"Perno","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2009.05.029_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/135965350100600306","article-title":"Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy","volume":"6","author":"Perno","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2009.05.029_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-131-11-199912070-00003","article-title":"HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed","volume":"131","author":"Zolopa","year":"1999","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653209002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653209002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T18:31:12Z","timestamp":1685039472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653209002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1386653209002017"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2009.05.029","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}